{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:22:44Z","timestamp":1791206564984,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,20]],"date-time":"2016-12-20T00:00:00Z","timestamp":1482192000000},"content-version":"am","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Novartis Inc"},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-09-1-0143"],"award-info":[{"award-number":["W81XWH-09-1-0143"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["CA-22453"],"award-info":[{"award-number":["CA-22453"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novartis Inc"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.urology.2015.08.008","type":"journal-article","created":{"date-parts":[[2015,9,13]],"date-time":"2015-09-13T04:26:31Z","timestamp":1442118391000},"page":"1206-1211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study"],"prefix":"10.1016","volume":"86","author":[{"given":"Ulka","family":"Vaishampayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Shevrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Heilbrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karri","family":"Stark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Dickow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryn","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2015.08.008_bib1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.urology.2015.08.008_bib2","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.urology.2015.08.008_bib3","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.urology.2015.08.008_bib4","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.urology.2015.08.008_bib5","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1464-410X.2007.07331.x","article-title":"Response to docetaxel\/carboplatin-based chemotherapy as first- and second-line therapy in\u00a0patients with metastatic hormone-refractory prostate cancer","volume":"101","author":"Nakabayashi","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2015.08.008_bib6","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1517\/13543780903362437","article-title":"Satraplatin: leading the new generation of oral platinum agents","volume":"18","author":"Bhargava","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.urology.2015.08.008_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cncr.23195","article-title":"A\u00a0phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel","volume":"112","author":"Ross","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.urology.2015.08.008_bib8","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00280-011-1734-5","article-title":"A\u00a0phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors","volume":"69","author":"Fury","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.urology.2015.08.008_bib9","unstructured":"Novartis Pharmaceuticals Corporation. Afinitor\u00ae (everolimus) tablets for oral administration [package insert]. Available at: http:\/\/www.rxlist.com\/afinitor-drug\/indications-dosage.htm. Accessed October 21, 2015."},{"key":"10.1016\/j.urology.2015.08.008_bib10","first-page":"10314","article-title":"Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP\/mTOR","volume":"18","author":"Neshat","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.urology.2015.08.008_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/CAD.0b013e3283400a20","article-title":"Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in\u00a0vitro and in\u00a0vivo","volume":"22","author":"O'Reilly","year":"2011","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.urology.2015.08.008_bib12","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/0008-5472.CAN-04-3137","article-title":"Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts","volume":"65","author":"Wu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2015.08.008_bib13","first-page":"6141","article-title":"Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells","volume":"62","author":"Gr\u00fcnwald","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2015.08.008_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur\u00a0J Cancer"},{"key":"10.1016\/j.urology.2015.08.008_bib15","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.urology.2015.08.008_bib16","series-title":"Statistical Models and Methods for Lifetime Data Analysis","author":"Lawless","year":"1982"},{"key":"10.1016\/j.urology.2015.08.008_bib17","series-title":"Statistical Methods for Survival Data Analysis","first-page":"76","author":"Lee","year":"2003"},{"key":"10.1016\/j.urology.2015.08.008_bib18","first-page":"7652","article-title":"Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder","volume":"63","author":"Knowles","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2015.08.008_bib19","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/CMR.0000000000000014","article-title":"Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Research Consortium","volume":"23","author":"Hauke","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.urology.2015.08.008_bib20","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urology.2015.08.008_bib21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1126\/science.1226344","article-title":"Genome sequencing identifies a basis for everolimus sensitivity","volume":"338","author":"Iyer","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.urology.2015.08.008_bib22","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2013.03.040","article-title":"Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08\/08)","volume":"64","author":"Templeton","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.08.008_bib23","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1464-410X.2012.11456.x","article-title":"Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer","volume":"110","author":"Nakabayashi","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2015.08.008_bib24","doi-asserted-by":"crossref","first-page":"7783","DOI":"10.1158\/0008-5472.CAN-05-4472","article-title":"Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins","volume":"66","author":"Xu","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.urology.2015.08.008_bib25","first-page":"11","article-title":"PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells","volume":"32","author":"Kaarb\u00f8","year":"2010","journal-title":"Cell Oncol"},{"key":"10.1016\/j.urology.2015.08.008_bib26","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1158\/1541-7786.MCR-14-0153-T","article-title":"HIF1\u03b1 regulates mTOR signaling and viability of prostate cancer stem cells","volume":"13","author":"Marhold","year":"2015","journal-title":"Mol Cancer Res"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429515007980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429515007980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T02:17:52Z","timestamp":1618193872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429515007980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0090429515007980"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2015.08.008","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2015.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}